LEADERSHIP
Experienced operators across development, regulatory and commercial strategy.
ReForma is led by a small senior team spanning pharmaceutical development, formulation and CMC, regulatory strategy and operations, drug-device combination products, commercial planning, partnering and corporate growth. Senior decision-making stays inside the company; execution runs through selected development partners
Leadership Team
Co-Founder, Executive Chair & Chief Executive Officer
Raj Sinhal
Raj co-founded ReForma and brings corporate finance and growth expertise built up over more than 30 years of backing and advising entrepreneurs and healthcare businesses. He has held national and international roles in professional services, including board member.
Imran co-founded ReForma to pursue reformulation as a discipline in its own right. He is a pharmaceutical scientist and regulatory leader with more than three decades of experience in global product development, regulatory strategy and CMC.
Imran Chaudry
Co-Founder & Chief Technical Officer
Joy Barclay
Joy co-founded ReForma and is a pharmaceutical commercial leader, strategist with more than 25 years of experience spanning clinical practice, clinical research, medical affairs, U.S. and global commercialization, and management consulting.
Co-Founder & Chief Commercial Officer
John Song
John co-founded ReForma and is a regulatory operations, systems expert with more than twenty-four years in the pharmaceutical industry. He has led global and United States submission filings and delivered NDA, BLA, NDS, and MAA dossiers to approval.
Co-Founder & Chief Operations Officer
Arun Ramachandran
Director, Product Development & Regulatory Affairs
Arun is a product development and regulatory affairs leader with 17 years of experience in the pharmaceutical industry, including roles in quality and regulatory affairs across the UK, Europe and international markets.
Scientific Advisory Board
ReForma's programs are reviewed and challenged by a scientific advisory board whose members bring experience across regulatory strategy, clinical pharmacology, safety and toxicology, neuroscience and drug-device development. The board stress-tests program strategy ahead of agency interactions and reviews technical and clinical plans at each decision point.
Meet Our Scientific Advisors
Phil Skolnick, Ph.D.,D.Sc.(hon.)
Dr. Skolnick has been widely recognized for foundational studies conducted at the NIH on the pharmacology and physiology of ligand-gated ion channels. These studies led to the demonstration that NMDA antagonists (like ketamine) have antidepressant properties.
Scientific Advisor
Dr. Susan Learned
Dr. Susan Learned, M.D., Pharm.D., Ph.D., is the President and Founder of Learned Consulting Group, LLC, which largely provides overall R&D, clinical pharmacology and medicines development strategic and execution support to pharmaceutical companies.
Scientific Advisor
Randal L Batenhorst
Randal Batenhorst, BS Pharm, PharmD, is a pharmaceutical, regulatory affairs executive with more than 35 years of combined global clinical development and regulatory affairs experience from candidate selection, clinical development, registration and product maintenance, which includes extensive advertising and promotion experience.
Scientific Advisor
Malcolm Young, Ph.D.
Dr. Malcolm Young is a Clinical Pharmacology consultant with more than 30 years of pharmaceutical industry experience, including senior roles at GSK (GlaxoSmithKline) and Indivior.
Scientific Advisor
Julie Tripp
Is an American Board of Toxicology diplomate, senior level toxicologist and nonclinical regulatory leader with extensive experience advancing CNS, addiction, and psychiatric therapeutics from pre–first-in-human development through post-marketing support.